Quantifying transient hypoxia in human tumor xenografts by flow cytometry

Cancer Research

Volumn 64, Issue 17, 2004, Pages 6183-6189

  Bennewith, Kevin L ^a   Durand, Ralph E ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PIMONIDAZOLE; TUMOR MARKER;

ARTICLE; CANCER THERAPY; COLON CARCINOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIC CELL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TISSUE OXYGENATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, SCID; NITROIMIDAZOLES; OXYGEN; PARTIAL PRESSURE; TRANSPLANTATION, HETEROLOGOUS; UTERINE CERVICAL NEOPLASMS;

EID: 4344707313     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0289     Document Type: Article

References (46)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst (Bethesda) 2001;93:266-76.
2. Arteel GE, Thurman RG, Yates JM, Raleigh JA. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer 1995;72:889-95,
3. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1 -yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs. bound radioactivity. Br J Cancer 1995;72: 869-74.
4. Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys 2001;49:569-74.
5. Olive PL, Durand RE, Raleigh JA, Luo C, Aquino-Parsons C. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br J Cancer 2000;83:1525-31.
6. Durand RE, Aquino-Parsons C. Non-constant tumour blood flow: implications for therapy. Acta Oncol 2001;40:862-9.
7. Durand RE, Aquino-Parsons C. Clinical relevance of intermittent tumour blood flow. Acta Oncol 2001;40:929-36.
8. Olive PL, Banath JP, Aquino-Parsons C. Measuring hypoxia in solid tumours: is there a gold standard? Acta Oncol 2001;40:917-23.
9. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 1996; 56:405-11.
10. Raleigh JA, Chou SC, Arteel GE, Horsman MR. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 1999;151:580-9.
11. Durand RE, Raleigh JA. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 1998;58:3547-50.
12. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984;10:695-712.
13. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-49.
14. Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979;52:650-6.
15. Denekamp J, Dasu A. Inducible repair and the two forms of tumour hypoxia: time for a paradigm shift. Acta Oncol 1999;38:903-18.
16. Durand RE. Intermittent blood flow in solid tumours: an under-appreciated source of 'drug resistance.' Cancer Metastasis Rev 2001;20:57-61.
17. Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996;56:5522-8.
18. 2 of R3230AC tumors in Fischer-344 rats. Int J Radiat Oncol Biol Phys 1998;42:723-6.
19. Braun RD, Lanzen JL, Dewhirst MW. Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats. Am J Physiol 1999;277:H551-68.
20. Brurberg KG, Graff BA, Rofstad EK. Temporal heterogeneity in oxygen tension in human melanoma xenografts. Br J Cancer 2003;89:350-6.
21. 2 fluctuations in human melanoma xenografts. Int J Radiat Oncol Biol Phys 2004;58:403-9.
22. Trotter MJ, Chaplin DJ, Durand RE, Olive PL. The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys 1989;16:931-4.
23. Trotter MJ, Chaplin DJ, Olive PL. Possible mechanisms for intermittent blood flow in the murine SCCVII carcinoma. Int J Radiat Biol 1991;60:139-46.
24. Durand RE, LePard NE. Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncol 1995;34:317-24.
25. Raleigh JA, Miller GG, Franko AJ, Koch CJ, Fuciarelli AF, Kelly DA. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br J Cancer 1987;56:395-400.
26. Franko AJ. Misonidazole and other hypoxia markers: metabolism and applications. Int J Radiat Oncol Biol Phys 1986;12:1195-202.
27. Iyer RV, Kim E, Schneider RF, Chapman JD. A dual hypoxic marker technique for measuring oxygenation change within individual tumors. Br J Cancer 1998;78:163-9.
28. Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J, Van Der Kogel AJ. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 2000;48:1529-38.
29. Chaplin DJ, Durand RE, Olive PL. Cell selection from a murine tumor using the fluorescent probe Hoechst 33342. Br J Cancer 1985;51:569-72.
30. Olive PL, Chaplin DJ, Durand RE. Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br J Cancer 1985;52:739-46.
31. Friedl F, Kimura I, Osato T, Ito Y. Studies on a new human cell line (SiHa) derived from carcinoma of uterus: I. Its establishment and morphology. Proc Soc Exp Biol Med 1970;135:543-5.
32. Noguchi P, Wallace R, Johnson J, et al. Characterization of the WIDR: a human colon carcinoma cell line. In Vitro 1979;15:401-8.
33. Durand RE. Use of Hoechst 33342 for cell selection from multicell systems. J Histochem Cytochem 1982;30:117-22.
34. Durand RE. Use of a cell sorter for assays of cell clonogenicity. Cancer Res 1986;46:2775-8.
35. Chaplin DJ, Durand RE, Olive PL. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 1986;12:1279-82.
36. Chaplin DJ, Hill SA, Bell KM, Tozer GM. Modification of tumor blood flow: current status and future directions. Semin Radiat Oncol 1998;8:151-63.
37. Walton MI, Bleehen NM, Workman P. Effects of localised tumour hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice. Br J Cancer 1989;59:667-73.
38. Bennewith KL, Raleigh JA, Durand RE. Orally administered pimonidazole to label hypoxic tumor cells. Cancer Res 2002;62:6827-30.
39. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001;13:167-71.
40. Vordermark D, Brown JM. Evaluation of hypoxia-inducible factor-1α (HIF-1α) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies. Int J Radiat Oncol Biol Phys 2003;56:1184-93.
41. Begg AC. Is HIF-1α a good marker for tumor hypoxia? Int J Radiat Oncol Biol Phys 2003:56:917-9.
42. Dewhirst MW, Kimura H, Rehmus SW, et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl 1996;27:S247-51.
43. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 1997;147:541-50.
44. Evans SM, Jenkins WT, Shapiro M, Koch CJ. Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status. Adv Exp Med Biol 1997;411: 215-25.
45. Olive PL, Banath JP, Durand RE. The range of oxygenation in SiHa tumor xenografts. Radiat Res 2002;158:159-66.
46. Saunders MI, Anderson PJ, Bennett MH, et al. The clinical testing of Ro 03-8799: pharmacokinetics, toxicology, tissue and tumor concentrations. Int J Radiat Oncol Biol Phys 1984;10:1759-63.